Mobilization of peripheral blood stem cells in patients with advanced thoracic malignancies after irinotecan (CPT-11) administration
Egusa, Y.; Fujiwara, Y.; Syaharuddin, E.; Sumiyoshi, H.; Isobe, T.; Yamakido, M.
Anticancer Research 18(1b): 481-487
1998
ISSN/ISBN: 0250-7005 PMID: 9568166 Document Number: 485845
We evaluated the mobilization of peripheral blood stem cells (PBSCs) after the administration of chemotherapy including irinotecan (CPT-11) in individuals with advanced thoracic malignancies including lung cancer and mesothelioma. All patients were previously untreated. The numbers of CD34+ cells, CD34+38- cells, and colony-forming units granulocyte macrophage (CFU-GM) in peripheral blood were determined to monitor PBSCs at least twice a week. Granulocyte colony stimulating factor (G-CSF) (75 mug/body per day) was administered at the onset of neutropenia (absolute neutrophil count (ANC) of < 1000/mul) until the ANC exceeded 5000/mul. In patients who received G-CSF, sufficient counts of the PBSCs for PBSC transplantation were mobilized at the time when the white blood cell count was >5000/mul. CPT-11 with G-CSF is thus a promising induction regimen for PBSC transplantation. Patients who did not develop neutropenia after chemotherapy showed a significantly (p= 0.005) higher number of CD34+ cells in the peripheral blood at steady state (median, 1818; range, 1534 to 4433; n=8) than those who developed neutropenia (median, 666; range, 608 to 1553; n =5). This parameter may thus prove a useful marker for predicting neutropenia after the administration of CPT-11.